Advertisement
Advertisement
IRLA
IRulya Therapeutics Inc. Common Stock
38.62
USDSponsored
+4.84
+14.34%
Nov 10, 15:59 UTC -5
Closed
After-Market
38.30
-0.32
-0.84%
IRulya Therapeutics Inc. Common Stock (IRLA) Earnings
IRLA Earnings Reports
Positive Surprise Ratio
IRLA beat 1 of 1 last estimates.
100%
Next Report
Today
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$3.66
Implied change from Q2 26 (Revenue/ EPS)
--
/-70.27%
Implied change from Q3 25 (Revenue/ EPS)
--
/-92.68%
IRulya Therapeutics Inc. Common Stock earnings per share and revenue
On Aug 14, 2026, IRLA reported earnings of -12.31 USD per share (EPS) for Q2 26, beating the estimate of -18.23 USD, resulting in a 32.50% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q3 26, -- analysts forecast an EPS of -3.66 USD, with revenue projected to reach -- USD, implying an decrease of -70.27% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ocular Therapeutix, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.54%
Harrow, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.22
Actual
$0.12
Surprise
-45.92%
SIGA Technologies Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-Actual
-$0.04
Surprise
-
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Tonix Pharmaceuticals Holding Corp.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$2.40
Actual
-$2.89
Surprise
-20.23%
Cumberland Pharmaceuticals Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
-$0.07
Surprise
-
PMV Pharmaceuticals, Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.23
Actual
-$1.81
Surprise
-46.07%
Heron Therapeutics, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-9.09%
FAQ
What were IRulya Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, IRulya Therapeutics Inc. Common Stock reported EPS of -$12.31, beating estimates by 32.5%, and revenue of $0.00, 0% as expectations.
How did the market react to IRulya Therapeutics Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is IRulya Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for IRulya Therapeutics Inc. Common Stock's next earnings report?
Based on --
analysts, IRulya Therapeutics Inc. Common Stock is expected to report EPS of -$3.66 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.